{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:10:37Z","timestamp":1789517437633,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.conctc.2022.100934","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T22:09:28Z","timestamp":1653689368000},"page":"100934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["ChemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and esophagogastric junction with oligometastases: Protocol of the TNT-OES-1 trial"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3650-8303","authenticated-orcid":false,"given":"Charl\u00e8ne J.","family":"van der Zijden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben M.","family":"Eyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ate","family":"van der Gaast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leni","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost J.M.E.","family":"Nuyttens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Jan B.","family":"van Lanschot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas P.L.","family":"Wijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd M.","family":"Lagarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.conctc.2022.100934_bib3","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1136\/gutjnl-2020-321600","article-title":"Global burden of oesophageal and gastric cancer by histology and subsite in 2018","volume":"69","author":"Arnold","year":"2020","journal-title":"Gut"},{"issue":"34","key":"10.1016\/j.conctc.2022.100934_bib4","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.3748\/wjg.v19.i34.5598","article-title":"Epidemiology of esophageal cancer","volume":"19","author":"Zhang","year":"2013","journal-title":"World J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.conctc.2022.100934_bib5","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","article-title":"Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial","volume":"3","author":"Al-Batran","year":"2017","journal-title":"JAMA Oncol."},{"issue":"22","key":"10.1016\/j.conctc.2022.100934_bib6","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.conctc.2022.100934_bib1","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S1470-2045(18)30201-8","article-title":"Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study","volume":"19","author":"Noordman","year":"2018","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.conctc.2022.100934_bib7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.conctc.2022.100934_bib8","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol."},{"issue":"10184","key":"10.1016\/j.conctc.2022.100934_bib9","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.conctc.2022.100934_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/bjs\/znaa121","article-title":"Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study","volume":"108","author":"Kamarajah","year":"2021","journal-title":"Br. J. Surg."},{"issue":"3","key":"10.1016\/j.conctc.2022.100934_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.29271\/jcpsp.2021.03.326","article-title":"CROSS or FLOT in distal esophageal and gastroesophageal cancer","volume":"31","author":"Karadag","year":"2021","journal-title":"J Coll Physicians Surg Pak"},{"issue":"15_suppl","key":"10.1016\/j.conctc.2022.100934_bib12","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.2021.39.15_suppl.4004","article-title":"Neo-AEGIS (neoadjuvant trial in adenocarcinoma of the esophagus and esophago-gastric junction international study): preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (modified MAGIC or FLOT protocol). (NCT01726452)","volume":"39","author":"John","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.conctc.2022.100934_bib13","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jtho.2017.03.017","article-title":"A prognostic scoring model for the utility of induction chemotherapy prior to neoadjuvant chemoradiotherapy in esophageal cancer","volume":"12","author":"Xi","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.conctc.2022.100934_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/COC.0000000000000524","article-title":"Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer","volume":"42","author":"Saba","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.conctc.2022.100934_bib15","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.7150\/jca.21131","article-title":"Comparative outcomes of induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma","volume":"8","author":"Luo","year":"2017","journal-title":"J. Cancer"},{"key":"10.1016\/j.conctc.2022.100934_bib16","unstructured":"Netherlands Trial Register. Combination of chemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and gastro-oesophageal junction with oligometastatic disease [cited 2021 Jul 29]. Available from https:\/\/www.trialregister.nl\/trial\/9269."},{"issue":"11","key":"10.1016\/j.conctc.2022.100934_bib17","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1046\/j.1365-2168.1998.00940.x","article-title":"Classification of adenocarcinoma of the oesophagogastric junction","volume":"85","author":"Siewert","year":"1998","journal-title":"Br. J. Surg."},{"issue":"2","key":"10.1016\/j.conctc.2022.100934_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.21037\/acs.2017.03.14","article-title":"8th edition AJCC\/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice","volume":"6","author":"Rice","year":"2017","journal-title":"Ann. Cardiothorac. Surg."},{"issue":"7","key":"10.1016\/j.conctc.2022.100934_bib19","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/jamaoncol.2015.3113","article-title":"JAMA oncology patient page. Performance Status in patients with cancer","volume":"1","author":"West","year":"2015","journal-title":"JAMA Oncol."},{"key":"#cr-split#-10.1016\/j.conctc.2022.100934_bib20.1","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE),Version 5.0 [updated 2017 Sep 27"},{"key":"#cr-split#-10.1016\/j.conctc.2022.100934_bib20.2","unstructured":"cited 2021 Jul 29]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"issue":"2","key":"10.1016\/j.conctc.2022.100934_bib2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.conctc.2022.100934_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2482-8-21","article-title":"Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS)","volume":"8","author":"van Heijl","year":"2008","journal-title":"BMC Surg."},{"issue":"5","key":"10.1016\/j.conctc.2022.100934_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"issue":"14","key":"10.1016\/j.conctc.2022.100934_bib23","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.ejca.2007.07.005","article-title":"Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach","volume":"43","author":"Lagergren","year":"2007","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.conctc.2022.100934_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann. Surg."},{"issue":"1","key":"10.1016\/j.conctc.2022.100934_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Contr. Clin. Trials"},{"key":"10.1016\/j.conctc.2022.100934_bib26","unstructured":"EORTC QLQ-C30 Scoring Manual, third ed., Brussels, 2001 [cited 2021 Jul 29]. Available from https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf."},{"issue":"suppl 5","key":"10.1016\/j.conctc.2022.100934_bib27","doi-asserted-by":"crossref","first-page":"v50","DOI":"10.1093\/annonc\/mdw329","article-title":"Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Lordick","year":"2016","journal-title":"Ann. Oncol."},{"key":"#cr-split#-10.1016\/j.conctc.2022.100934_bib28.1","unstructured":"Richtlijnendatabase Oesofaguscarcinoom, Federatie Medisch Specialisten. [updated 2010 Dec 1"},{"key":"#cr-split#-10.1016\/j.conctc.2022.100934_bib28.2","unstructured":"cited 2021 Jul 29]. Available from: https:\/\/richtlijnendatabase.nl\/richtlijn\/oesofaguscarcinoom\/oesofaguscarcinoom_-_startpagina.html."},{"key":"10.1016\/j.conctc.2022.100934_bib29","unstructured":"Integraal Kankercentrum Nederland. Overleving slokdarm- en maagkanker. [cited 2021 Jul 29]. Available from: https:\/\/iknl.nl\/kankersoorten\/slokdarm-en-maagkanker\/registratie\/overleving."},{"issue":"3","key":"10.1016\/j.conctc.2022.100934_bib30","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s10147-018-1239-x","article-title":"A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma","volume":"23","author":"Hiramoto","year":"2018","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.conctc.2022.100934_bib31","first-page":"412","article-title":"Nimotuzumab combined with chemotherapy is a promising treatment for locally advanced and metastatic esophageal cancer","volume":"23","author":"Han","year":"2017","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin. Res."},{"issue":"12","key":"10.1016\/j.conctc.2022.100934_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doz034","article-title":"Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study","volume":"32","author":"Seesing","year":"2019","journal-title":"Dis. Esophagus"},{"issue":"1","key":"10.1016\/j.conctc.2022.100934_bib33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/dote.12034","article-title":"Radiofrequency ablation for pulmonary metastases from esophageal squamous cell carcinoma","volume":"27","author":"Baba","year":"2014","journal-title":"Dis. Esophagus"},{"issue":"5","key":"10.1016\/j.conctc.2022.100934_bib34","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3109\/02656736.2016.1155758","article-title":"Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: preliminary results and literature review","volume":"32","author":"Zhou","year":"2016","journal-title":"Int. J. Hyperther."},{"issue":"1","key":"10.1016\/j.conctc.2022.100934_bib35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1186\/s12885-017-3918-9","volume":"17","author":"Al-Batran","year":"2017","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.conctc.2022.100934_bib36","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1245\/s10434-017-5830-6","article-title":"TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG","volume":"24","author":"Leong","year":"2017","journal-title":"Ann. Surg Oncol."},{"issue":"1","key":"10.1016\/j.conctc.2022.100934_bib37","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1186\/s12885-018-4770-2","volume":"18","author":"Slagter","year":"2018","journal-title":"BMC Cancer"}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865422000515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865422000515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:07:43Z","timestamp":1762520863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865422000515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":39,"alternative-id":["S2451865422000515"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2022.100934","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ChemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and esophagogastric junction with oligometastases: Protocol of the TNT-OES-1 trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2022.100934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100934"}}